Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02

Kojiro Shimozuma, Yasuo Ohashi, Ayano Takeuchi, Toshihiko Aranishi, Satoshi Morita, Katsumasa Kuroi, Shozo Ohsumi, Haruhiko Makino, Hirohumi Mukai, Noriyuki Katsumata, Yoshihide Sunada, Toru Watanabe, Frederick H. Hausheer

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Goals: The aim of the study was to determine the feasibility and validity of a newly developed patient-based instrument-the Patient Neurotoxicity Questionnaire (PNQ)-for grading chemotherapy-induced peripheral neuropathy (CIPN). Patients and methods: We prospectively collected data from 300 female patients who were treated with taxane chemotherapy for primary breast cancer as part of a national multicenter phase III randomized trial (N-SAS BC 02). We evaluated patient compliance with the PNQ and several validation parameters, including concordance between CIPN grades noted by physicians (National Cancer Institute Common Toxicity Criteria) and patients (PNQ), and the concurrent validity and responsiveness of the PNQ versus the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) utilizing data at pre-treatment and before three, five, and seven treatment cycles. Main results: The questionnaire completion rate was >90% at all assessments. Evaluation by physicians always resulted in lower neuropathy assessment scores compared with those reported directly by patients (weighted kappa coefficients, 0.02-0.06). Both PNQ sensory and motor scores were significantly correlated with the FACT/GOG-Ntx (r∈=∈0.66 and 0.51, respectively). In the repeated measures analysis of variance model, PNQ grades increased considerably as treatment continued, indicating progressively worsening CIPN over time. Conclusions: The PNQ has an applicable degree of feasibility and validity, useful for the diagnosis of CIPN as well as for clinical treatment decision-making, where the development of CIPN is a potential treatment-limiting consideration. Physicians underreport and underestimate the severity of CIPN symptoms compared with patients, thereby supporting the importance of assessing patient-reported outcomes using the PNQ.

Original languageEnglish
Pages (from-to)1483-1491
Number of pages9
JournalSupportive Care in Cancer
Volume17
Issue number12
DOIs
Publication statusPublished - 2009 Dec
Externally publishedYes

Keywords

  • Neurotoxicity
  • Patient Neurotoxicity Questionnaire (PNQ) Validation
  • Patient-reported outcomes
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02'. Together they form a unique fingerprint.

  • Cite this

    Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., Kuroi, K., Ohsumi, S., Makino, H., Mukai, H., Katsumata, N., Sunada, Y., Watanabe, T., & Hausheer, F. H. (2009). Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Supportive Care in Cancer, 17(12), 1483-1491. https://doi.org/10.1007/s00520-009-0613-7